Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Bavarian Nordic signs up U.S. firm for packaging monkeypox vaccine

by Staff GBAF Publications Ltd
0 comment

(Reuters) – Danish biotech firm Bavarian Nordic said on Thursday it has signed up a U.S.-based manufacturer to package its Jynneos monkeypox vaccine and the production is expected to begin later this year.

The company aims to finish the technology transfer in three months to Michigan-based Grand River Aseptic.

More than 13,500 cases of the disease, which cause flu-like symptoms and skin lesions, have been reported in the United States as of Aug. 17.

The government’s Biomedical Advanced Research and Development Authority, which procures the vaccine, has requested 5.5 million doses for delivery this year and the next, the company said.

This includes an additional order for 2.5 million doses that Bavarian Nordic received last month.

Besides allowing faster deliveries to the United States, the agreement will free up the company’s capacity for other countries.

The Danish company has doubled its capacity from before the outbreak started in May and expects to further increase it even as it explores more partnerships to improve global access to the vaccine.

To boost the supply of monkeypox vaccines, the United States is making an additional 1.8 million doses of the Jynneos vaccine available for orders starting Aug. 22.

Cases of monkeypox have been rising globally, with over 38,800 cases confirmed.

 

(Reporting by Amruta Khandekar and Leroy Leo; Editing by Shailesh Kuber and Arun Koyyur)